Customer Experience In The Biotech Industry Statistics 2026

Seventy-two percent of consumers expect real-time help when they contact a company. In the same care journey, one in 10 patients still reports they do not understand how to take their medicines. In biotech, those communication gaps compound adherence risk, and preventable readmissions cost an estimated $17.4 billion each year.

Key Takeaways

31% of patients stopped taking their medication due to side effects, making patient experience a measurable driver of treatment adherence in oncology settings
80% of patients said it was important that their provider was empathetic, indicating a strong link between interpersonal experience and perceived care quality
66% of patients reported higher stress when wait times were long, quantifying how scheduling and access experiences affect patient outcomes
72% of consumers expect real-time assistance when contacting a company, demonstrating the interaction expectations that biotech customer experience programs must meet
67% of service organizations report improving customer experience is a top driver of digital transformation investment
73% of biopharma companies plan to increase digital engagement with healthcare professionals over the next 24 months
38% of life sciences organizations have adopted or are planning to adopt patient portals, showing a measurable digital CX channel expansion trend
41% of customers cite trust as the most important factor in their relationship with a company, underscoring CX’s reputational component for biotech credibility
In the US, the average hospital measures are standardized via CAHPS; CAHPS includes item sets for patient experience benchmarking
2.6% of patients report they did not receive required discharge instructions, a quantifiable experience metric tied to avoidable utilization
1 in 10 patients reports not understanding how to take their medicines, quantifying experience-related comprehension gaps that increase safety and waste costs
$1.4 billion was the cost of health misinformation in 2020 in the US (quantifying the downstream CX/communication burden that biotech must reduce)
Up to 30% of healthcare spending is estimated to be waste, implying that poor experience and process inefficiencies can contribute to avoidable cost
The estimated cost of avoidable readmissions in the US is about $17.4 billion annually, linking care transition experience to measurable financial impact
26% of patients reported that they experienced care delays related to scheduling and access issues, indicating that wait and appointment experience remains a material CX factor in healthcare delivery.

Patients expect empathetic, clear communication and fast, easy access because experience gaps directly drive adherence and costs.

01 · Category

Patient Experience6 stats

31% of patients stopped taking their medication due to side effects, making patient experience a measurable driver of treatment adherence in oncology settings

80% of patients said it was important that their provider was empathetic, indicating a strong link between interpersonal experience and perceived care quality

66% of patients reported higher stress when wait times were long, quantifying how scheduling and access experiences affect patient outcomes

2.9x higher likelihood of patients reporting a better overall experience when staff communicate clearly, measured through patient-reported experience outcomes

52% of patients say they want more communication about side effects, indicating a measurable demand for ongoing experience touchpoints

36% of patients report skipping or not using medication because of access or complexity barriers, quantifying the experience impact on treatment continuity

Interpretation

Patient Experience Interpretation

For patient experience in biotech care, delays and weak communication have measurable consequences, since 66% of patients report higher stress with long wait times and 31% stop their medication due to side effects, while clear staff communication is linked to a 2.9x better overall experience.

02 · Category

Digital Experience2 stats

72% of consumers expect real-time assistance when contacting a company, demonstrating the interaction expectations that biotech customer experience programs must meet

67% of service organizations report improving customer experience is a top driver of digital transformation investment

Interpretation

Digital Experience Interpretation

In the biotech digital experience, 72% of consumers expect real time assistance and 67% of service organizations are prioritizing digital transformation investment to improve customer experience, making instant support a clear driver of CX-focused digital strategy.

03 · Category

Industry Trends4 stats

73% of biopharma companies plan to increase digital engagement with healthcare professionals over the next 24 months

38% of life sciences organizations have adopted or are planning to adopt patient portals, showing a measurable digital CX channel expansion trend

41% of customers cite trust as the most important factor in their relationship with a company, underscoring CX’s reputational component for biotech credibility

47% of organizations reported that improving patient outcomes is a key objective of CX initiatives in healthcare

Interpretation

Industry Trends Interpretation

With 73% of biopharma companies planning to boost digital engagement over the next 24 months and 38% already adopting patient portals, biotech customer experience is clearly trending toward faster, more accessible digital interactions that aim to build trust and improve patient outcomes.

04 · Category

Performance Metrics5 stats

In the US, the average hospital measures are standardized via CAHPS; CAHPS includes item sets for patient experience benchmarking

2.6% of patients report they did not receive required discharge instructions, a quantifiable experience metric tied to avoidable utilization

1 in 10 patients reports not understanding how to take their medicines, quantifying experience-related comprehension gaps that increase safety and waste costs

31% of patients say they did not receive help understanding medication side effects, a measurable experience gap relevant to biotech support and communication

17% of patients in a US survey said they experienced problems with obtaining prescription refills, measuring a specific CX failure point for therapy continuity

Interpretation

Performance Metrics Interpretation

Performance metrics in biotech care show that meaningful patient-experience failures are common, with 31% reporting they did not get help understanding medication side effects and another 17% reporting prescription refill problems, alongside 2.6% lacking required discharge instructions and 1 in 10 not understanding how to take medicines.

05 · Category

Cost Analysis8 stats

$1.4 billion was the cost of health misinformation in 2020 in the US (quantifying the downstream CX/communication burden that biotech must reduce)

Up to 30% of healthcare spending is estimated to be waste, implying that poor experience and process inefficiencies can contribute to avoidable cost

The estimated cost of avoidable readmissions in the US is about $17.4 billion annually, linking care transition experience to measurable financial impact

In the US, preventable adverse drug events cost an estimated $3.5 billion annually, connecting experience and communication failures to cost

Each minute of delay in clinical decision-making is associated with increased clinical risk, quantifying responsiveness experience requirements in time-sensitive care pathways

A 1% decrease in call center abandonment is associated with measurable improvements in resolution outcomes and operating costs (benchmark used in contact center performance management)

1 in 5 patients experience nonadherence due to regimen complexity, which increases cost and reduces value from biotech therapies

22% of patients report they would pay more for a better healthcare experience, quantifying willingness-to-pay as an economic lever for CX

Interpretation

Cost Analysis Interpretation

In cost analysis, the evidence shows that improving customer experience in biotech is not just a service goal but a cost lever, since health misinformation alone cost the US $1.4 billion in 2020 and preventable adverse drug events add another $3.5 billion annually, while waste in healthcare spending up to 30% suggests experience and process inefficiencies can drive large avoidable expenses.

Customer Experience In IndustryCustomer Experience In The Bpo Industry Statistics

06 · Category

Patient Access2 stats

26% of patients reported that they experienced care delays related to scheduling and access issues, indicating that wait and appointment experience remains a material CX factor in healthcare delivery.

30.1% of U.S. adults reported they postponed seeing a doctor or dentist when they needed care due to cost, underscoring that financial experience and access challenges can interrupt care pathways relevant to biotech.

Interpretation

Patient Access Interpretation

In the patient access lens, 26% of patients report scheduling and access-related care delays and 30.1% of U.S. adults put off needed doctor or dentist visits due to cost, showing that both operational and financial barriers are widely undermining timely healthcare access.

07 · Category

Digital Engagement2 stats

80% of patients report using websites or digital channels to learn more about their condition and treatment, suggesting digital information experience is a key CX component in healthcare journeys that biotech supports.

70% of patients say they want to be able to message their care team for questions, emphasizing the demand for asynchronous communication channels in patient experience.

Interpretation

Digital Engagement Interpretation

With 80% of patients relying on websites or digital channels for condition and treatment information and 70% wanting the ability to message their care team, digital engagement is clearly shifting from just learning online to expecting two way digital communication in biotech customer experience.

08 · Category

Service Communication2 stats

49% of customers say they will switch brands due to poor service, showing that customer experience failures can translate into measurable churn risk.

54% of patients reported that they did not receive all the information they needed about their medicines, highlighting that medication education and communication quality remain measurable CX issues.

Interpretation

Service Communication Interpretation

In service communication, the fact that 49% of customers will switch brands after poor service and 54% of patients say they did not get all the information they needed about their medicines shows that clear, complete interactions directly shape retention and patient confidence.

09 · Category

Compliance & Trust2 stats

3 in 10 patients reported having at least one medication-related problem, underscoring the need for compliant, trustworthy medication support experiences.

22% of U.S. adults reported receiving conflicting information about health or medical matters, highlighting a communication trust challenge that can affect patient experience in healthcare ecosystems.

Interpretation

Compliance & Trust Interpretation

With 3 in 10 patients reporting medication-related problems and 22% of U.S. adults getting conflicting health information, the compliance and trust challenge in biotech is clearly tied to ensuring medications are handled correctly and that patients receive consistent, credible guidance.

10 · Category

Outcomes & Cost1 stats

$17.4 billion estimated annual cost of preventable readmissions in the United States, connecting care transition experience with measurable financial impact.

Interpretation

Outcomes & Cost Interpretation

The estimated $17.4 billion annual cost of preventable readmissions in the United States shows how improving care transition experiences can directly reduce measurable outcomes and costs in the biotech industry.

report visual · Key figures

Biotech CX priorities: expectations vs gaps

Patient experience is tightly linked to outcomes (adherence, stress, clarity), while key information and support gaps remain—especially around medication understanding, side effects, and refills.

80%

80% of patients said it was important that their provider was empathetic, indicating a strong link between interpersonal

52%

52% of patients say they want more communication about side effects, indicating a measurable demand for ongoing experien

31%

31% of patients say they did not receive help understanding medication side effects, a measurable experience gap relevan

17%

17% of patients in a US survey said they experienced problems with obtaining prescription refills, measuring a specific

70%

70% of patients say they want to be able to message their care team for questions, emphasizing the demand for asynchrono

80%

80% of patients report using websites or digital channels to learn more about their condition and treatment, suggesting

source-verifiedahrq.gov · ncbi.nlm.nih.gov · healthaffairs.org · jamanetwork.com

Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA

Helena Kowalczyk. (2026, February 13). Customer Experience In The Biotech Industry Statistics. Gitnux. https://gitnux.org/customer-experience-in-the-biotech-industry-statistics

MLA

Helena Kowalczyk. "Customer Experience In The Biotech Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/customer-experience-in-the-biotech-industry-statistics.

Chicago

Helena Kowalczyk. 2026. "Customer Experience In The Biotech Industry Statistics." Gitnux. https://gitnux.org/customer-experience-in-the-biotech-industry-statistics.